Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study.

ABSTRACT:

Background

Although CD19 and CD22 chimeric antigen receptor (CAR-T) cell therapies have demonstrated encouraging clinical responses in patients with B-cell lymphoma, over 50% of patients ultimately experience disease progression due to frequent antigen escape. The development of CD19/CD22 dual-target CAR-T cells holds promise for overcoming this limitation; however, their clinical application is currently challenging because of insufficient targeting of CD22.

Methods

In this study, we engineered CD19/CD22 BS Loop CAR-T cells with an enhanced targeting efficacy for CD22 and assessed their safety and effectiveness in patients with relapsed/refractory diffuse large B-cell lymphoma.

Results

Among the five patients who received CD19/CD22 bispecific Loop CAR-T-cell therapy

SUBMITTER: Li S 

PROVIDER: S-EPMC12804173 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature